title: Hybrid (COPP/ABV) therapy in childhood Hodgkin's disease: a study of 53 cases during 1989-1993 at the Cancer Institute, Madras.
abstract: The optimal therapy for children with Hodgkin's disease is controversial. Between 1989 and 1993, 53 children under 14 years of age with Hodgkin's disease were treated with COPP/ABV (cyclophosphamide, vincristine, procarbazine, prednisolone/adriamycin, bleomycin, vinblastine) hybrid chemotherapy. The results were analyzed with the Kaplan-Meier product limit method for survival and the Logrank test for predicting statistical significance. Ten patients (18.87%) had early-stage disease (I to IIA) and 43 (81.13%) had advanced disease. Lymphocyte-predominant histology was seen in 20 (37.5%) patients, nodular sclerosis in 8 (15%), mixed cellularity in 21 (39.6%), and lymphocyte depletion in 4 (7.56%). The male:female ratio was 3.82:1. Complete responses were seen in 51 (96.22%) patients, with 47 (92.15%) of them in sustained first remission. The event-free survival rate is 90.3% to date. COPP/ABV hybrid chemotherapy is an effective primary therapy for all stages of Hodgkin's disease in children.
authors.affiliation: Division of Medical Oncology, Cancer Institute, Madras, India.
authors.forename: P V
authors.initials: PV
authors.lastname: Sripada
authors.forename: S G
authors.initials: SG
authors.lastname: Tenali
authors.forename: M
authors.initials: M
authors.lastname: Vasudevan
authors.forename: S
authors.initials: S
authors.lastname: Viswanadhan
authors.forename: D
authors.initials: D
authors.lastname: Sriraman
authors.forename: R
authors.initials: R
authors.lastname: Kandasamy
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone